MAGI2

Summary

MAGI2 (membrane associated guanylate kinase, WW and PDZ domain containing 2, HGNC:18957) is a protein-coding gene on chromosome 7q21.11, encoding Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (Q86UL8). Seems to act as a scaffold molecule at synaptic junctions by assembling neurotransmitter receptors and cell adhesion proteins.

The protein encoded by this gene interacts with atrophin-1. Atrophin-1 contains a polyglutamine repeat, expansion of which is responsible for dentatorubral and pallidoluysian atrophy. This encoded protein is characterized by two WW domains, a guanylate kinase-like domain, and multiple PDZ domains. It has structural similarity to the membrane-associated guanylate kinase homologue (MAGUK) family.

Source: NCBI Gene 9863 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nephrotic syndrome 15 (Strong, GenCC) — +3 more curated relationships
• GWAS associations: 40
• Clinical variants (ClinVar): 656 total — 6 pathogenic, 8 likely-pathogenic
• Phenotypes (HPO): 20
• MANE Select transcript: NM_012301

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18957
Approved symbol	MAGI2
Name	membrane associated guanylate kinase, WW and PDZ domain containing 2
Location	7q21.11
Locus type	gene with protein product
Status	Approved
Aliases	AIP1, ARIP1, KIAA0705, ACVRIP1, MAGI-2
Ensembl gene	ENSG00000187391
Ensembl biotype	protein_coding
OMIM	606382
Entrez	9863

Gene structure

Transcript identifiers

Ensembl transcripts: 41 — 19 protein_coding_CDS_not_defined, 18 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000354212, ENST00000419488, ENST00000440555, ENST00000519748, ENST00000520379, ENST00000522342, ENST00000522391, ENST00000524268, ENST00000524316, ENST00000626691, ENST00000628361, ENST00000628781, ENST00000628997, ENST00000629359, ENST00000630991, ENST00000634996, ENST00000635863, ENST00000635961, ENST00000636039, ENST00000636040, ENST00000636178, ENST00000636234, ENST00000636424, ENST00000636593, ENST00000636717, ENST00000636936, ENST00000636989, ENST00000636993, ENST00000637074, ENST00000637136, ENST00000637249, ENST00000637282, ENST00000637441, ENST00000637486, ENST00000637515, ENST00000637585, ENST00000637728, ENST00000637824, ENST00000637879, ENST00000637976, ENST00000676103

RefSeq mRNA: 2 — MANE Select: NM_012301 NM_001301128, NM_012301

CCDS: CCDS5594, CCDS75623

Canonical transcript exons

ENST00000354212 — 22 exons

Exon	Start	End
ENSE00001021144	78078947	78079085
ENSE00001205406	78521430	78521645
ENSE00001303965	79007090	79007206
ENSE00001330729	78501577	78501787
ENSE00001597225	79453020	79453667
ENSE00003485835	78194874	78195063
ENSE00003514874	78489761	78489840
ENSE00003524896	78369156	78369213
ENSE00003529450	78132889	78133060
ENSE00003541745	78125694	78125837
ENSE00003542108	78185629	78185670
ENSE00003543935	78127197	78127416
ENSE00003556812	78345922	78346043
ENSE00003575979	78135021	78135206
ENSE00003603486	78627120	78627239
ENSE00003608927	78343778	78343960
ENSE00003611156	78201162	78201193
ENSE00003629425	78255943	78256581
ENSE00003629946	78167916	78168108
ENSE00003660829	78178011	78178102
ENSE00003683137	78160025	78160273
ENSE00003850706	78017055	78019976

Expression profiles

Bgee: expression breadth ubiquitous, 267 present calls, max score 97.59.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.7553 / max 631.5590, expressed in 1188 samples.

FANTOM5 promoters (17 alternative TSS)

Promoter ID	TPM avg	Samples expressed
84504	3.1489	826
84506	2.7145	766
84491	1.2845	212
84481	1.2476	161
84489	1.1118	170
84502	0.8861	305
84503	0.8083	345
84488	0.4275	97
84480	0.2602	88
84478	0.2386	88

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	97.59	gold quality
corpus callosum	UBERON:0002336	96.88	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.76	gold quality
middle temporal gyrus	UBERON:0002771	96.15	gold quality
renal glomerulus	UBERON:0000074	95.97	gold quality
metanephric glomerulus	UBERON:0004736	95.96	gold quality
adrenal tissue	UBERON:0018303	95.20	gold quality
Brodmann (1909) area 46	UBERON:0006483	94.38	gold quality
parietal lobe	UBERON:0001872	93.94	gold quality
entorhinal cortex	UBERON:0002728	93.93	gold quality
postcentral gyrus	UBERON:0002581	93.87	gold quality
primary visual cortex	UBERON:0002436	93.72	gold quality
lateral globus pallidus	UBERON:0002476	93.64	gold quality
occipital lobe	UBERON:0002021	93.59	gold quality
sural nerve	UBERON:0015488	93.17	gold quality
CA1 field of hippocampus	UBERON:0003881	93.00	gold quality
superior frontal gyrus	UBERON:0002661	92.69	gold quality
cranial nerve II	UBERON:0000941	92.66	gold quality
subthalamic nucleus	UBERON:0001906	92.35	gold quality
superior vestibular nucleus	UBERON:0007227	92.04	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.89	gold quality
medulla oblongata	UBERON:0001896	91.80	gold quality
dorsal plus ventral thalamus	UBERON:0001897	91.65	gold quality
inferior vagus X ganglion	UBERON:0005363	91.65	gold quality
ventricular zone	UBERON:0003053	91.61	gold quality
temporal lobe	UBERON:0001871	91.37	gold quality
orbitofrontal cortex	UBERON:0004167	91.12	gold quality
globus pallidus	UBERON:0001875	91.05	gold quality
substantia nigra pars reticulata	UBERON:0001966	90.64	gold quality
ventral tegmental area	UBERON:0002691	90.63	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-131882	yes	44025.04
E-CURD-119	yes	41522.65
E-CURD-135	yes	2112.81
E-HCAD-35	yes	91.85
E-HCAD-10	yes	20.48
E-ANND-3	yes	9.91
E-GEOD-93593	no	282.88
E-MTAB-7381	no	175.87
E-MTAB-7303	no	129.63

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ZNF699

miRNA regulators (miRDB)

99 targeting MAGI2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-6124	99.87	69.78	3551

Literature-anchored findings (GeneRIF, showing 32)

• PTEN plays a critical role in MAGI-2-induced inhibition of cell migration and proliferation in human hepatocarcinoma cells (PMID:17880912)
• Interstitial deletions that include the MAGI2 gene on chromosome 7q11.23-q.21.11 are associated with IS cases. (PMID:18565486)
• MAGI2 genetic variation is associated with inflammatory bowel disease. (PMID:18720471)
• Data show that AIP1 is a novel GTPase-activating protein for Arf6, a small GTPase regulating cellular PIP(2) production and formation of the TLR4-TIRAP-MyD88 complex. (PMID:19948740)
• analysis of 7q11.21-q11.23 and infantile spasms without deletion of MAGI2 [case report] (PMID:20101691)
• there was no association of MAGI2 and PARD3 with IBD. (PMID:21515326)
• Results presented herein provide further evidence for a role of MAGI2 in bipolar affective disorder and schizophrenia etiology. (PMID:22381734)
• Common variants in MAGI2 gene are associated with increased risk for cognitive impairment in schizophrenic patients. (PMID:22649501)
• MAGI2 enhances the sensitivity of BEL-7404 human hepatocellular carcinoma cells to staurosporine-induced apoptosis by increasing PTEN stability. (PMID:23754155)
• Data show that the miR-134/487b/655 cluster regulates TGF-beta1-induced epithelial-mesenchymal transition and affected the resistance to gefitinib by directly targeting membrane-associated guanylate kinase, WW, and PDZ domain-containing protein 2 (MAGI2). (PMID:24258346)
• In Usher syndrome 1G, mutations in SANS eliminate Magi2 binding and thereby deregulate endocytosis, lead to defective ciliary transport modules and ultimately disrupt photoreceptor cell function inducing retinal degeneration. (PMID:24608321)
• The expression of MAGI2 mRNA was significantly down-regulated in PC3, LNCaP and DU-145 PCa cell lines. (PMID:24985972)
• MAGI2, SERPINE2, and NT5C3B expression levels are associated with airway wall thickening and additionally with bronchial inflammation, emphysema, and lung function, respectively, all features of chronic obstructive pulmonary disease. (PMID:25517131)
• MAGI-2 immunoreactivity is elevated in prostate cancer and high-grade prostatic intraepithelial neoplasia compared with normal tissue, suggesting that MAGI-2 may contribute to prostate carcinogenesis. (PMID:26980016)
• MAGI-2 could represent a useful adjunct for diagnosis of prostatic adenocarcinoma (PMID:27543977)
• Immunohistochemistry in kidney sections from these patients revealed that mutations resulted in lack of or diminished podocyte MAGI2 expression. Our data support the finding that mutations in the MAGI2 gene are causal for congenital steroid-resistant nephrotic syndrome (PMID:27932480)
• MAGI2 expression is reduced during prostate cancer progression and that retention of MAGI2 signal reduces odds of biochemical recurrence. Decreased MAGI2 expression may help predict prostate cancer aggressiveness. (PMID:29542165)
• MAGI2-AS3 plays an important role as a tumour suppressor by targeting Fas and FasL signalling. (PMID:29679339)
• MAGI2 gene polymorphism rs2160322 is associated with Graves’ disease and not with Hashimoto’s thyroiditis. (PMID:30535759)
• Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2. (PMID:31171376)
• LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25. (PMID:32138716)
• MAGI-2 downregulation: a potential predictor of tumor progression and early recurrence in Han Chinese patients with prostate cancer. (PMID:32167077)
• HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer. (PMID:32581010)
• MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2. (PMID:32730644)
• Polymorphism in the MAGI2 Gene Modifies the Effect of Amyloid beta on Neurodegeneration. (PMID:33323781)
• Comparative study of immunohistochemical expression of ERG and MAGI2 in prostatic carcinoma. (PMID:33713943)
• Novel insights for lncRNA MAGI2-AS3 in solid tumors. (PMID:33761624)
• GLIDR promotes the progression of glioma by regulating the miR-4677-3p/MAGI2 axis. (PMID:34237299)
• Genetic variants of SDCCAG8 and MAGI2 in mitosis-related pathway genes are independent predictors of cutaneous melanoma-specific survival. (PMID:34375487)
• The TLR4/NF-kappaB/MAGI-2 signaling pathway mediates postoperative delirium. (PMID:35294925)
• LncRNA MAGI2-AS3-Encoded Polypeptide Restrains the Proliferation and Migration of Breast Cancer Cells. (PMID:37358745)
• MAGI2 ameliorates podocyte apoptosis of diabetic kidney disease through communication with TGF-beta-Smad3/nephrin pathway. (PMID:37950637)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	magi2b	ENSDARG00000073769
mus_musculus	Magi2	ENSMUSG00000040003
rattus_norvegicus	Magi2	ENSRNOG00000013962

Paralogs (6): MAGI3 (ENSG00000081026), GRIP2 (ENSG00000144596), MAGI1 (ENSG00000151276), SAV1 (ENSG00000151748), GRIP1 (ENSG00000155974), MAGIX (ENSG00000269313)

Protein

Protein identifiers

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 — Q86UL8 (reviewed: Q86UL8)

Alternative names: Atrophin-1-interacting protein 1, Atrophin-1-interacting protein A, Membrane-associated guanylate kinase inverted 2

All UniProt accessions (18): A0A0D9SET0, A0A0D9SEY4, A0A0D9SEZ7, A0A0D9SF86, A0A0D9SFP3, A0A0D9SFY9, A0A0D9SGF2, A0A0D9SGF8, A0A0U1RRH4, A0A1B0GTC0, A0A1B0GTH8, A0A1B0GUF0, A0A1B0GUI9, A0A1B0GUV4, A0A1B0GVS0, A0A1B0GVS6, Q86UL8, E7EWI0

UniProt curated annotations — full annotation on UniProt →

Function. Seems to act as a scaffold molecule at synaptic junctions by assembling neurotransmitter receptors and cell adhesion proteins. Plays a role in nerve growth factor (NGF)-induced recruitment of RAPGEF2 to late endosomes and neurite outgrowth. May play a role in regulating activin-mediated signaling in neuronal cells. Enhances the ability of PTEN to suppress AKT1 activation. Plays a role in receptor-mediated clathrin-dependent endocytosis which is required for ciliogenesis.

Subunit / interactions. Interacts (via its WW domains) with DRPLA. Interacts (via its second PDZ domain) with PTEN (via unphosphorylated C-terminus); this interaction diminishes the degradation rate of PTEN. Interacts (via guanylate kinase domain) with DLGAP1. Interacts (via the PDZ domains) with GRIN2A, GRID2 and NLGN1. Interacts with CTNND2, CTNNB1, MAGUIN-1, ACVR2A, SMAD2 and SMAD3. Part of a complex consisting of MAGI2/ARIP1, ACVR2A, ACVR1B and SMAD3. May interact with HTR2A. Interacts with IGSF9, RAPGEF2 and HTR4. Identified in a complex with ACTN4, CASK, IQGAP1, NPHS1, SPTAN1 and SPTBN1. Found in a complex, at least composed of KIDINS220, MAGI2, NTRK1 and RAPGEF2; the complex is mainly formed at late endosomes in a NGF-dependent manner. Interacts with RAPGEF2; the interaction occurs before or after nerve growth factor (NGF) stimulation. Interacts (via PDZ domain) with KIDINS220 (via C-terminal domain). Interacts with DDN. Interacts with DLL1. Found in a complex with IGSF9B and NLGN2; the interaction with IGSF9B is mediated via the PDZ 5 and PDZ 6 domains, while the interaction with NLGN2 is mediated via the WW1, WW2 and PDZ2 domains. Interacts (via PDZ 6 domain) with USH1G (via SAM domain); the interaction is triggered by phosphorylation of USH1G by CK2 and negatively regulates MAGI2-mediated endocytosis.

Subcellular location. Cytoplasm. Late endosome. Synapse. Synaptosome. Cell membrane. Cytoskeleton. Microtubule organizing center. Centrosome. Cell projection. Cilium. Centriole. Photoreceptor inner segment. Photoreceptor outer segment.

Tissue specificity. Specifically expressed in brain.

Disease relevance. Nephrotic syndrome 15 (NPHS15) [MIM:617609] A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. NPHS15 is an autosomal recessive form with onset in the first months of life. Disease severity is variable. Some patients show rapid progression to end-stage renal failure. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the MAGUK family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q86UL8-1	1	yes
Q86UL8-2	2

RefSeq proteins (2): NP_001288057, NP_036433* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001202	WW_dom	Domain
IPR001478	PDZ	Domain
IPR008144	Guanylate_kin-like_dom	Domain
IPR008145	GK/Ca_channel_bsu	Domain
IPR020590	Guanylate_kinase_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR036020	WW_dom_sf	Homologous_superfamily
IPR036034	PDZ_sf	Homologous_superfamily

Pfam: PF00397, PF00595, PF00625, PF16663

UniProt features (87 total): strand 29, sequence conflict 13, compositionally biased region 10, helix 10, domain 9, modified residue 6, region of interest 5, turn 3, chain 1, splice variant 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
1UEP	SOLUTION NMR
1UEQ	SOLUTION NMR
1UEW	SOLUTION NMR
1UJV	SOLUTION NMR
1WFV	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UL8-F1	61.10	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 362, 686, 827, 884, 885, 1014

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-373753	Nephrin family interactions
R-HSA-1500931	Cell-Cell communication

MSigDB gene sets: 296 (showing top): GOBP_SMAD_PROTEIN_SIGNAL_TRANSDUCTION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, GOBP_EPITHELIAL_CELL_DEVELOPMENT, GOBP_NON_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_NEUROGENESIS, KEGG_TIGHT_JUNCTION, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_KIDNEY_EPITHELIUM_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_RECEPTOR_MEDIATED_ENDOCYTOSIS, MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_RESPONSE_TO_NERVE_GROWTH_FACTOR

GO Biological Process (16): positive regulation of receptor internalization (GO:0002092), signal transduction (GO:0007165), nervous system development (GO:0007399), negative regulation of cell population proliferation (GO:0008285), positive regulation of neuron projection development (GO:0010976), negative regulation of cell migration (GO:0030336), negative regulation of activin receptor signaling pathway (GO:0032926), nerve growth factor signaling pathway (GO:0038180), receptor clustering (GO:0043113), negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051898), Wnt signaling pathway, planar cell polarity pathway (GO:0060071), SMAD protein signal transduction (GO:0060395), podocyte development (GO:0072015), clathrin-dependent endocytosis (GO:0072583), cellular response to nerve growth factor stimulus (GO:1990090), endocytosis (GO:0006897)

GO Molecular Function (7): phosphatase binding (GO:0019902), signaling receptor complex adaptor activity (GO:0030159), beta-1 adrenergic receptor binding (GO:0031697), SMAD binding (GO:0046332), type II activin receptor binding (GO:0070699), protein binding (GO:0005515), kinase activity (GO:0016301)

GO Cellular Component (23): photoreceptor outer segment (GO:0001750), photoreceptor inner segment (GO:0001917), nucleus (GO:0005634), cytoplasm (GO:0005737), late endosome (GO:0005770), centrosome (GO:0005813), centriole (GO:0005814), plasma membrane (GO:0005886), cell-cell junction (GO:0005911), bicellular tight junction (GO:0005923), postsynaptic density (GO:0014069), dendrite (GO:0030425), protein-containing complex (GO:0032991), slit diaphragm (GO:0036057), synapse (GO:0045202), perinuclear region of cytoplasm (GO:0048471), ciliary base (GO:0097546), endosome (GO:0005768), cytoskeleton (GO:0005856), cilium (GO:0005929), membrane (GO:0016020), cell projection (GO:0042995), neuron projection (GO:0043005)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Cell-Cell communication	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
microtubule organizing center	2
intracellular membraneless organelle	2
regulation of receptor internalization	1
receptor internalization	1
positive regulation of receptor-mediated endocytosis	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
system development	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
regulation of neuron projection development	1
neuron projection development	1
positive regulation of cell projection organization	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
activin receptor signaling pathway	1
regulation of activin receptor signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
neurotrophin signaling pathway	1
cellular response to nerve growth factor stimulus	1
plasma membrane	1
protein localization to membrane	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
negative regulation of intracellular signal transduction	1
non-canonical Wnt signaling pathway	1
cell surface receptor protein serine/threonine kinase signaling pathway	1
intracellular signaling cassette	1
podocyte differentiation	1
glomerular epithelial cell development	1
receptor-mediated endocytosis	1
cellular response to growth factor stimulus	1
response to nerve growth factor	1
vesicle budding from membrane	1

Protein interactions and networks

STRING

1336 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAGI2	PTEN	P60484	974
MAGI2	CACNG2	Q9Y698	912
MAGI2	NLGN1	Q8N2Q7	877
MAGI2	RAPGEF2	Q9Y4G8	861
MAGI2	MAST2	Q6P0Q8	840
MAGI2	CTNNB1	P35222	809
MAGI2	NLGN2	Q8NFZ4	800
MAGI2	TAMALIN	Q7Z6J2	769
MAGI2	MAST1	Q9Y2H9	761
MAGI2	NLGN3	Q9NZ94	758
MAGI2	NLGN4X	Q8N0W4	731
MAGI2	NLGN4Y	Q8NFZ3	718
MAGI2	DAG1	Q14118	648
MAGI2	CTNND2	Q9UQB3	633
MAGI2	DLGAP1	P78335	625

IntAct

1855 interactions, top by confidence:

A	B	Type	Score
MAGI2	ADRB1	psi-mi:“MI:0407”(direct interaction)	0.830
E	MAGI2	psi-mi:“MI:0915”(physical association)	0.710
E	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.710
MAGI2	E	psi-mi:“MI:0915”(physical association)	0.710
MAGI2	E	psi-mi:“MI:0407”(direct interaction)	0.710
TGFA	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.620
E6	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.610
MAGI2	E6	psi-mi:“MI:0407”(direct interaction)	0.610
PTEN	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.610
MAGI2	PTEN	psi-mi:“MI:0407”(direct interaction)	0.610
RPS6KA1	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.610
SLC15A5	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.610
MAGI2	SLC15A5	psi-mi:“MI:0915”(physical association)	0.610
FZD7	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.610
MAGI2	E6	psi-mi:“MI:0915”(physical association)	0.610
MAGI2	Tax	psi-mi:“MI:0407”(direct interaction)	0.610
MAGI2	Tax	psi-mi:“MI:0915”(physical association)	0.610

BioGRID (55): BAI1 (Reconstituted Complex), TTBK1 (Co-fractionation), MAGI2 (Affinity Capture-MS), ERBB4 (Affinity Capture-Western), MAGI2 (Reconstituted Complex), MAGI2 (Affinity Capture-Western), PTEN (Affinity Capture-Western), MAGI2 (Affinity Capture-Western), MAGI2 (Protein-peptide), CRHR1 (Reconstituted Complex), MAGI2 (Two-hybrid), MAGI2 (Two-hybrid), MAGI2 (Two-hybrid), MAGI2 (Two-hybrid), MAGI2 (Two-hybrid)

ESM2 similar proteins: A0A0G2K2P5, A0JNJ1, B1WAP7, G9CGD6, O14640, O75122, O88382, O95049, O97758, P34908, P39447, P51141, P54792, P70175, Q05AS8, Q07157, Q16825, Q5F488, Q5IS48, Q5SGD7, Q5TCQ9, Q5XI81, Q61062, Q62136, Q62728, Q62936, Q6DKE2, Q6P9H4, Q6ZM86, Q812E4, Q86UL8, Q8BMA3, Q8IVH8, Q8JHI3, Q8TDW5, Q920B0, Q924I2, Q925T6, Q92997, Q95168

Diamond homologs: A0A0G2K2P5, A0A8P0N4K0, C5IAW9, F1LW30, O08721, O08722, O08747, O62683, O95049, O95185, O97758, P39447, P57105, Q07157, Q0P5E6, Q13424, Q28626, Q32LE7, Q3T0C9, Q5EBL8, Q5ZIK2, Q61234, Q6NXB2, Q6QA76, Q6R653, Q6UXZ4, Q6ZN44, Q761X5, Q7KRY7, Q7T2Z5, Q80VW5, Q86UL8, Q8IV45, Q8IZJ1, Q8JGT4, Q8K1S2, Q8K1S3, Q8K1S4, Q95168, Q9CZG9

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
NLGN2	“up-regulates activity”	MAGI2	binding
MAGI2	“up-regulates activity”	DGC	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 123 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neurexins and neuroligins	6	14.6×	6e-04
Cardiac conduction	7	9.4×	8e-04
Neurotransmitter receptors and postsynaptic signal transmission	7	8.7×	9e-04
Cell-Cell communication	5	8.5×	1e-02
Muscle contraction	8	7.6×	8e-04
Transmission across Chemical Synapses	7	6.6×	4e-03
Neuronal System	9	4.9×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of synaptic transmission, glutamatergic	8	43.4×	8e-09
positive regulation of excitatory postsynaptic potential	5	22.9×	5e-04
learning or memory	6	12.6×	1e-03
synapse organization	5	12.2×	5e-03
synapse assembly	6	12.0×	2e-03
social behavior	5	11.8×	5e-03
cell-cell adhesion	11	9.7×	1e-05
calcium ion transmembrane transport	5	9.2×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

656 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	8
Uncertain significance	363
Likely benign	144
Benign	92

Top pathogenic / likely-pathogenic (14)

Variant ID	HGVS	Classification
1527367	GRCh37/hg19 7q11.23-21.11(chr7:77310644-84461089)	Pathogenic
2425793	NC_000007.13:g.(?77530028)(79082636_?)del	Pathogenic
3011499	NM_012301.4(MAGI2):c.159_174del (p.Tyr54fs)	Pathogenic
431755	NM_012301.4(MAGI2):c.3998del (p.Gly1333fs)	Pathogenic
431756	NM_012301.4(MAGI2):c.64_71del (p.Arg22fs)	Pathogenic
431757	NM_012301.4(MAGI2):c.3526_3533dup (p.Glu1178fs)	Pathogenic
1683652	NM_012301.4(MAGI2):c.147del (p.Gly50fs)	Likely pathogenic
253354	GRCh37/hg19 7q21.11(chr7:77972816-78186999)x1	Likely pathogenic
253370	GRCh37/hg19 7q21.11(chr7:77972816-79082129)x1	Likely pathogenic
3594849	NM_012301.4(MAGI2):c.2269+2dup	Likely pathogenic
3594897	NM_012301.4(MAGI2):c.712G>T (p.Glu238Ter)	Likely pathogenic
3594912	NM_012301.4(MAGI2):c.79C>T (p.Gln27Ter)	Likely pathogenic
4081507	NM_012301.4(MAGI2):c.1390del (p.Asp464fs)	Likely pathogenic
4847529	NM_012301.4(MAGI2):c.3567+1G>T	Likely pathogenic

SpliceAI

5661 predictions. Top by Δscore:

Variant	Effect	Δscore
7:78078943:GTA:G	donor_loss	1.0000
7:78078944:TAC:T	donor_loss	1.0000
7:78078945:A:AC	donor_gain	1.0000
7:78078946:C:CA	donor_loss	1.0000
7:78078946:C:CC	donor_gain	1.0000
7:78079082:CTAC:C	acceptor_gain	1.0000
7:78079084:ACCT:A	acceptor_loss	1.0000
7:78079085:CCTGT:C	acceptor_loss	1.0000
7:78079086:C:CA	acceptor_loss	1.0000
7:78125837:CCTT:C	acceptor_gain	1.0000
7:78125846:T:TC	acceptor_gain	1.0000
7:78135019:AC:A	donor_gain	1.0000
7:78135019:ACCCT:A	donor_gain	1.0000
7:78135020:CC:C	donor_gain	1.0000
7:78135020:CCCTC:C	donor_gain	1.0000
7:78135062:T:TA	donor_gain	1.0000
7:78135202:CACAG:C	acceptor_gain	1.0000
7:78135203:ACAG:A	acceptor_gain	1.0000
7:78135204:CAG:C	acceptor_gain	1.0000
7:78135204:CAGC:C	acceptor_gain	1.0000
7:78135207:C:CC	acceptor_gain	1.0000
7:78135207:CT:C	acceptor_loss	1.0000
7:78160021:TTA:T	donor_loss	1.0000
7:78160022:TA:T	donor_loss	1.0000
7:78160023:A:AC	donor_gain	1.0000
7:78160023:A:C	donor_loss	1.0000
7:78160024:C:CT	donor_gain	1.0000
7:78160044:AGG:A	donor_gain	1.0000
7:78167911:CATA:C	donor_loss	1.0000
7:78167912:ATACC:A	donor_loss	1.0000

AlphaMissense

9541 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:78078979:A:G	L1225P	1.000
7:78078985:A:G	L1223P	1.000
7:78079012:A:T	I1214N	1.000
7:78079015:A:G	L1213P	1.000
7:78079025:C:G	A1210P	1.000
7:78079063:A:C	I1197S	1.000
7:78079072:A:C	I1194S	1.000
7:78125740:A:G	L1174S	1.000
7:78125779:A:T	I1161N	1.000
7:78125781:G:C	S1160R	1.000
7:78125781:G:T	S1160R	1.000
7:78125783:T:G	S1160R	1.000
7:78125784:G:C	F1159L	1.000
7:78125784:G:T	F1159L	1.000
7:78125785:A:G	F1159S	1.000
7:78125786:A:G	F1159L	1.000
7:78125788:C:T	G1158E	1.000
7:78125790:A:C	F1157L	1.000
7:78125790:A:T	F1157L	1.000
7:78125791:A:G	F1157S	1.000
7:78125792:A:G	F1157L	1.000
7:78135041:A:G	L1004P	1.000
7:78135041:A:T	L1004H	1.000
7:78135047:A:T	V1002D	1.000
7:78135060:C:G	A998P	1.000
7:78135068:A:C	I995S	1.000
7:78135068:A:T	I995N	1.000
7:78135071:A:G	L994P	1.000
7:78135088:G:C	H988Q	1.000
7:78135088:G:T	H988Q	1.000

dbSNP variants (sampled 300 via entrez): RS1000000249 (7:78713207 C>A), RS1000000520 (7:79281159 C>T), RS1000000780 (7:78154224 A>G), RS1000002077 (7:79026511 G>A,T), RS1000002918 (7:79157293 C>T), RS1000004175 (7:79150779 T>A,G), RS1000004312 (7:78445504 A>T), RS1000006090 (7:78512491 C>A,T), RS1000007627 (7:78413850 G>A,C), RS1000008714 (7:78284394 T>C), RS1000009324 (7:78212120 T>C), RS1000010338 (7:79072052 C>T), RS1000011058 (7:78592653 C>G,T), RS1000011693 (7:78196066 C>T), RS1000012318 (7:78839645 C>T)

Disease associations

OMIM: gene MIM:606382 | disease phenotypes: MIM:617609, MIM:181500

GenCC curated gene-disease

Disease	Classification	Inheritance
nephrotic syndrome 15	Strong	Autosomal recessive
familial idiopathic steroid-resistant nephrotic syndrome	Supportive	Autosomal dominant
genetic developmental and epileptic encephalopathy	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
epilepsy	Refuted	AD

Mondo (5): nephrotic syndrome 15 (MONDO:0033262), prostate cancer (MONDO:0008315), schizophrenia (MONDO:0005090), familial idiopathic steroid-resistant nephrotic syndrome (MONDO:0019006), genetic developmental and epileptic encephalopathy (MONDO:0100062)

Orphanet (2): Familial prostate cancer (Orphanet:1331), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

20 total (21 of 20 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000093	Proteinuria
HP:0000097	Focal segmental glomerulosclerosis
HP:0000707	Abnormality of the nervous system
HP:0000737	Irritability
HP:0000969	Edema
HP:0001945	Fever
HP:0001967	Diffuse mesangial sclerosis
HP:0002027	Abdominal pain
HP:0002315	Headache
HP:0002586	Peritonitis
HP:0003073	Hypoalbuminemia
HP:0003593	Infantile onset
HP:0003774	Stage 5 chronic kidney disease
HP:0011947	Respiratory tract infection
HP:0012579	Minimal change glomerulonephritis
HP:0012588	Steroid-resistant nephrotic syndrome
HP:0012622	Chronic kidney disease
HP:0031504	Foamy urine
HP:0100539	Periorbital edema
HP:0100753	Schizophrenia

GWAS associations

40 associations (top):

Study	Trait	p-value
GCST000461_4	Hippocampal atrophy	3.000000e-06
GCST001308_7	Response to anti-depressant treatment in major depressive disorder	3.000000e-06
GCST001693_8	Acute lymphoblastic leukemia (childhood)	5.000000e-06
GCST001762_274	Obesity-related traits	3.000000e-06
GCST002104_21	Bronchopulmonary dysplasia	6.000000e-06
GCST002667_5	Mammographic density (dense area)	2.000000e-06
GCST002783_195	Body mass index	2.000000e-06
GCST002783_350	Body mass index	2.000000e-07
GCST002794_1	Airway wall thickness	6.000000e-07
GCST002794_17	Airway wall thickness	2.000000e-06
GCST002794_7	Airway wall thickness	1.000000e-06
GCST002831_9	Lead levels in blood	4.000000e-06
GCST003542_193	Night sleep phenotypes	8.000000e-06
GCST004862_81	Itch intensity from mosquito bite adjusted by bite size	3.000000e-06
GCST004904_38	Body mass index	8.000000e-10
GCST004946_51	Schizophrenia	4.000000e-08
GCST005024_9	Pursuit maintenance gain	1.000000e-06
GCST005173_67	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	3.000000e-07
GCST005175_55	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes	1.000000e-07
GCST006137_14	Serum folate levels	9.000000e-06
GCST006151_2	Memory dysfunction in frontotemporal lobe dementia	5.000000e-06
GCST007201_11	Schizophrenia	3.000000e-06
GCST007325_13	General risk tolerance (MTAG)	8.000000e-09
GCST007576_177	Chronotype	9.000000e-09
GCST008473_45	Visceral fat	6.000000e-06
GCST008521_26	Bitter beverage consumption	6.000000e-07
GCST009028_54	Adverse response to drug	8.000000e-08
GCST009359_1	LDL cholesterol levels x short total sleep time interaction (1df test)	2.000000e-06
GCST009365_3	LDL cholesterol levels x short total sleep time interaction (2df test)	3.000000e-09
GCST009365_7	LDL cholesterol levels x short total sleep time interaction (2df test)	3.000000e-11

EFO canonical traits (20, from GWAS)

EFO ID	Trait name
EFO:0005039	hippocampal atrophy
EFO:0006322	antidepressant-induced sexual dysfunction
EFO:0003940	physical activity
EFO:0005941	mammographic density measurement
EFO:0006503	dense area measurement
EFO:0004340	body mass index
EFO:0006898	airway wall thickness measurement
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0008433	pursuit maintenance gain measurement
EFO:0004723	coronary artery calcification
EFO:0001072	memory impairment
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement
EFO:0010089	bitter beverage consumption measurement
EFO:0009658	adverse effect
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0010368	lysophosphatidylethanolamine 18:1 measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0004574	total cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	8
Benzo(a)pyrene	increases mutagenesis, affects methylation, decreases expression, decreases methylation	5
Aflatoxin B1	decreases expression, decreases methylation, increases methylation	4
bisphenol A	decreases methylation, increases expression, affects methylation, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Nickel	decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, decreases methylation	1
tungsten carbide	affects binding, decreases expression	1
methylmercuric chloride	decreases expression	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	affects methylation	1
cobaltous chloride	increases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	increases expression	1
zinc chromate	decreases expression, increases abundance	1
benzo(e)pyrene	increases methylation	1
didecyldimethylammonium	increases expression	1
N-acetyl-4-benzoquinoneimine	affects response to substance	1
aflatoxin B2	increases methylation	1
chromium hexavalent ion	decreases expression, increases abundance	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
perfluoro-n-nonanoic acid	increases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9IZ	Ubigene HEK293 MAGI2 KO	Transformed cell line	Female

Clinical trials (associated diseases)

312 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer